Building on this neuropathological staging, the NIA‐AA described a tau‐PET uptake‐based biological staging system that integrates amyloid status and the extent and intensity of tau‐PET signal, providing a standardized approach to stage AD in vivo.27 This evidence concerns the gene MAPT and amyloidosis.